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Urinary growth activity during accelerated serum sickness in rabbits.
J. L. Alix, L. Tranqui, A. Duperray, P. Couderc, F. Chenais, and D.
Cordonnier. INSERM Unite 217, Centre d'Energie Nucléaire de Gre-
noble, and Service de Nephrologie, Centre Hospitalier Regional de
Grenoble, Grenoble, France. Glomerular cell proliferation is a feature
of several patterns of glomerulonephritis (GN). Numerous data indicate
that platelets are involved in ON. The release of platelet-derived growth
factors might promote glomerular cell proliferation. We have studied
growth activity in the urine during accelerated serum sickness GN in
rabbits. GN was induced with a protocol derived from that used by
Shigematsu and Kobayashi. The determination of proteinuria, hematu-
na, renal histology, and immunohistology corroborated that GN was
induced. Growth activity of the urine was assessed by studying the
suppression of the growth contact inhibition of Balb/C—3 T3 cells.
Before the determination of the growth activity, the urine samples were
dialyzed using membranes of various cut off to separate growth factors
of different molecular weights. A growth activity related to between
6,000 and 15,000 daltons was observed in the urine of healthy animals.
It decreased during the course of GN. On the other hand, a growth
activity related to a molecular weight superior to 10,000 to 15,000
appeared only during GN. This activity was not found in the urine of
healthy animals and its highest level is observed on day II after GN
induction. The conditions for the appearance of the growth factor and
its molecular weight observed during the course of ON are consistent
with the characteristics of the platelet-derived growth factor. Further
biochemical studies are necessary to support these data.
Study of blood, Ca, Mg, and trace element (Mn, Pb, Cu, Zn, Si, and
Ba) concentrations in hemodialyzed patients during hyperaluminemia test
(HAT) by desferrioxamine (DFA). K. S. Ang, P. Allain, Y. Mauras, and
P. Simon. Médècine E Service (Nephrology), C. H. La Beauchée, Si-
Brieuc, and Pharmacology Laboratory, C.H. U. Angers, Angers,
France. The aim of this work was to evaluate whether the administra-
tion of DFA in hemodialyzed patients was able to modify the blood
levels of Ca, Mg, and trace elements (Mn, Pb, Cu, Zn, Si, and Ba). Each
dosage was measured in whole blood with fiameless atomic absorption
spectrophotometer. Twenty-six hemodialyzed patients from 2 to 17
years were studied. Blood samples were measured before (N1) and at
the end (N2) of the hemodialysis (HD) session (without DFA), then
during HAT by DFA. The test was performed by infusion of DFA in
doses of 2 g at the time of HD session. Aluminum levels in whole blood
were measured before (T1) and after (T2) infusion, then 48 hr later
before (T3) and after (T4) a next session (without DFA). Blood trace
element levels were measured as T1-T2 and T3-T4 and were compared
with control values N1-N2. Results were as follows: Al(.tg/liter): N1, 58
41;N2, 58 38 (NS); T1, 35 41; T2, 88 68 (P <0.001); T3, 137
77; T4, 84 52 (P <0.001). Ca (mg/liter): N1, 64 11; N2, 72 13 (P <
0.02);Ti,66± ll;T2,73± l6(P<0.02);T3,66± 14;T4;75±23(P
<0.02). Mg (mg/liter): N1, 39 5; N2, 38 5 (NS); T1, 40 6; T2, 39
7 (NS); T3, 39 6; T4, 40 7 (NS). Mn (pg/liter): N1, 10.02 5.36; N2,
11.19 6.02 (NS); T1, 8.73 3.43; T2, 10.16 5.16 (NS); T3, 8.92
3.69; T4, 10.38 4.14 (NS). Pb (Wliter): N1, 142 42; N2, 126 37
(NS);T1, 107 56; T2, 125 78 (NS); T3, 124 57; T4, 129 67 (NS).
Cu(sg/l): N1, 985 158; N2, 1026 194 (NS); T1, 1057 194; T2, 1105
211 (NS);T3, 1077 210;T4, 1192 235(NS). Zn(tgIliter): N1,4440
975;N2,4812 1038 (P <0.001); T1, 4490 947;T2, 4821 1231 (P
<0.001); T3, 4254 1096; T4, 5096 1279(P<0.00l).Si(sg/liter):N1,
2231 669; N2, 1525 246 (P< 0.001); T1, 2808 442;T2, 1939 315
(P < 0.001); T3, 2742 402; T4, 1897 294. Ba (sg/liter): T,, 2.73
1.99; T2, 3.31 4.17 (NS); T3, 2.68 2.07; T4, 3.25 1.70 (NS). In
conclusion, (1) blood aluminum increases significantly after administra-
tion of DFA. (2) The DFA does not modify the blood levels of Mg and
trace elements (Mn, Pb, Cu, and Ba). (3) The increase of Ca and Zn
levels and the decrease of Si levels during each hemodialysis session
were not modified by DFA.
Renal needle biopsy: Blind or ultrasonically guided procedure? A
prospective randomized study. B. Branger, R. Oules, P. Bouzigues, J.
M. Bourgeois, and J. Fourcade, Nephrology Department and Ultra-
sonography Department, CHRU Nimes, France. Since April 1980, we
have developed an original technique for renal needle biopsy (RNB)
with permanent ultrasonic guidance (PUG) which allowed us to control
continuously the needle progression through soft tissues and the lower
pole of the kidney. Correct aseptic conditions were maintained, and this
procedure provided valuable results in some "high risk" RNB indica-
tions such as obesity, chronic or acute respiratory failure, spinal
deformations, and single kidney. This prompted us to start a random-
ized prospective study in December 1981 to compare the classical blind
RNB and this new PUG technique in patients without any particular
risk factor. Results from the first 14 months have been analyzed. Forty-
three RNB were performed during this period. Thirteen of them had to
be excluded from the randomized procedure (unavailability of the
selected nephrologist or echographist, five patients; renal transplant,
four patients; acute respiratory distress, four patients). Comparison of
PUG RNB (N = 14) vs. blind RNB (N = 16) shows, respectively (mean
I SD): mean duration of the procedure 17 mm II, vs. 18 12(NS);
total biopsy length (for each patient) 17 mm 7 vs. 21 9 (NS);
number of punctures 2.8 1.1 vs. 4.0 2.0 (P < 0.05). Histological
results are:
Blind RNB PUG RNB
Adequate renal tissue 93.8% 92.9%
More than 10 glomeruli 56.3% 85.7%
Less than 10 glomeruli 37.5% 7.1%
Cortex and medulla 25.0% 7.1%
Medulla alone 6.3% 0.0%
No renal tissue 0.0% 7.1%
PVG RNB seems to provide the same amount of renal tissue with a
better quality (more glomeruli) than does blind biopsy, with significant-
ly less punctures of the kidney. The sole failure with PUG RNB was
explained by fibrosis surrounding the kidney. This study is still in
progress to confirm the superiority of PUG RNB.
Effect of mitomycin C on the biosynthesis of prostacyclin by primary
cultures of human umbilical cord vein endothelial cells. A. Duperray, L.
Tranqui, J. L. Alix, M. Manoeuvrier and D. Cordonnier. Unite 217
Laboratoire d' Hématologie, C.E.N.G., andService de Nephrologie,
Centre Hospitalier Regional de Grenoble, Grenoble, France. Mitomy-
cm c is now considered one of the etiological agents of the hemolytic
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and uremic syndrome (HUS). Since a deficiency in the synthesis of
prostacyclin has been suggested as a triggering factor in HUS, we have
measured the effect of Mitomycin C on the biosynthesis of prostacyclin
by primary cultures of endothelial cells isolated from human umbilical
cord vein. The cells are cultured in 199 media containing 30% of human
serum on an extracellular matrix of fibronectin. The cells are used at
confluency. The production of prostacyclin is measured by radioim-
munoassay of 6 keto PGFIa. In the resting state, the 6 keto PGFIa
production is 350 41 pg/l0 mnIlO6 cells. In the presence of 5 U/mI of
thrombin, the synthesis is increased, 4430 520 pg/IO mnIlO6 cells. In
the presence of 3 sgIml of mitomycin C, thrombin-induced synthesis is
decreased, 3204 200 pg/I0 mn/106 cells. Preincubating the cells for 24
hr with 3 ,ug/ml of mitomycin is followed by further decreased prostacy-
din production, 2171 220 pg/b mn/106 cells. In our experimental
conditions, at doses close to the values found in serum during human
therapy, mitomycin C induced modifications in the rate of prostacyclin
synthesis. These results support the hypothesis of a role of PGI2
deficiency in the occurrence of HUS.
Ilemolytic and uremic syndrome (HUS) in children: Effect of plasma on
the production of prostacyclin (PGI2) by rat aortic rings. N. Schiegel, C.
Loirat, J. Maclouf, R. Marotte, L. Drouet, and H. Mathieu. Labora-
loire Central d'Hématologie et Immunologie; Clinique de Pédiatrie,
HOpital Bretonneau; INSERM Unite 150, Hôpital Lariboisière, Paris,
France. The description of a defect of PG!2 production was first
reported in 1978 in adult patients with HUS. The purpose of our work
was to study PGI2 production in children with HUS by measuring the
effect of these patients' plasma on PGI2 synthesis by rat aortic walls.
Twenty-three children with HUS, 6 months to 16 years old, were
studied (glomerular thrombotic microangiopathy (TMA), 11 patients;
cortical necrosis, 5 patients; arterial TMA, 1 patient). The effect of the
patient plasma obtained before fresh-frozen plasma (FFP) infusion was
compared to the effect of control plasma (ten age-matched normal
children). The concentration of P012 in aortic incubates was determined
at 10, 20, 30, 40 and 60 mm of incubation, by radioimmunoassay of 6-
keto PGF1,, (ng/mg of dried aortic tissue). The results were as follows:
(1) The 6-keto PFGI. production obtained with normal plasma was not
higher than that obtained with buffer alone. These results are quite
similar to those published elsewhere with a method similar to ours
(using incompletely "exhausted" rings). These results differ from
others who used a different method (completely "exhausted" rings). (2)
The 6-keto PGFJ,, production (ng/mg) obtained with HUS children
plasma was (mean I SD): 1.59 0.43 at 10 mm; 2.39 0.74 at 20 mm;
3.03 0.87 at 30 mm; 3.93 1.08 at 40 mm; 4.49 1.36 at 60 mm.
These values are not significantly different from those of controls. In
one patient with recurrent HUS, the concentration of 6-keto PFG1 was
in the normal range during two episodes of the disease. In two patients,
FFP infusion (10 mI/weight kg) did not induce a significant variation in
the amount of 6-keto PGF1,, released. The results obtained with the
plasma of the patient with arterial TMA were also within the normal
range. These observations differ from those published by authors. In
conclusion, the differences between the results reported by various
authors for normal plasma and patient plasma could be related to
methodologic differences and/or to patient heterogeneity. It therefore
appears that the concept of a plasmatic factor stimulating PG!2 vascular
synthesis cannot be considered as an incontestable argument for the
choice of therapeutic trials to be proposed to patients with HUS.
Tuberous sclerosis (TS) with chronic renal failure (CRF): Microscopic
examination after repeated renal biopsies. F. Schillinger, R. Montagnac,
J. L. Grapin, P. Birembaut, and C. Hopfner. Service de Néphrologie-
Hémodialyse et Laboratoire d'Anatomie-Pathologique dii CHG de
Troyes and Laboratoire Pol Bouin du CHU de Reims, Reims, France.
CRF, rarely seen in TS, is usually related to renal localizations of
hematomas and/or cysts but is only rarely linked to glomerular and
interstitial lesions. In July 1981, typical cutaneous signs and evaluation
of the CRF led to diagnosis of TS in a 32-year-old male. There was also
a cerebral localization without clinical symptoms and cysts and angio-
myolipomas in both normal-sized kidneys. There was no positive family
history, but one of two daughters, with only one HLA identity to her
father, suffered from TS. Nonselective proteinuria (6 g/24 hr) without
hypertension or hematuria was present, progressing slowly to nephrotic
syndrome. Immunological study was normal; no infection was detect-
ed. Two renal biopsies, done at a 20-month interval (creatinine clear-
ance, respectively, at 70 and 34 mI/mn) showed focal and segmental
glomerulosclerosis with vascular and interstitial lesions, more severe at
the time of the second biopsy. Hypertension subsequently appeared in
March 1983 and further deterioration in renal function in August 1983
(creatinine clearance at 15 mI/mn). Our histopathologic study at early
and then at advanced stages of CRF indicates that the decrease in renal
function, often related only to the renal involvement with multiple
tumors, in this patient is associated with progression of glomerulo-
sclerosis and interstitial lesions. It would be a new example of renal
injury due to hyperfiltration: Nephronic reduction linked to renal
tumors leads to hemodynamic overload in remaining glomeruli, causing
glomerular sclerosis and progressive renal destruction.
Comparative study of aluminum clearance according to dialysis tech-
niques and membranes during hyperaluminemia test (HAT) by desfer-
rioxamine (DFA) in hemodialyzed patients. P. Simon, K. S. Ang, G.
Cam, A. Brigand, Y. Mauras, and P. AIlain. Service de Médecine-
Nephrologie, C. H. La Beauchée, Saint-Brieuc, and Laboratoire de
Pharmacologie, C.H. U. Angers, France. The aim of this work was to
evaluate in 40 hemodialyzed patients aluminum clearance (CAI mI/mn)
during HAT by DFA according to dialysis techniques and membranes:
hemodialysis using a closed circuit (Rhodial 75) with high permeability
membrane (ANH2_10 HOSPAL) (CCH12) or cuprophane (CCCup),
open circuit hemodialysis with cuprophane (OCCup) or high permeabil-
ity membrane (OCH12), and hemofiltration (Sartorius) with filtral
membrane (HOSPAL) (HFF). Fifteen patients were treated by CCH12,
10 CCCup, 11 OCCup, 2OCH2, and 2 HFF. The HAT by DFA was
performed by infusion of DFA in doses of 2 g during the hemodialysis or
hemofiltration session. Serum Al values were measured before (T1) and
after (T2) infusion, then 2 days later before (T3) and after (T4) a next
session (without DFA). Serum aluminum levels were measured in
dialysate (Ald sg/liter) and in ultrafiltrate (AIUF sg/liter) at T1, T2, T3,
and T4. The CAl was calculated with the following equation:
T4—T3 A1D or A1UF (ig/l) x blood inflow (mI/mm)
T4 + T3
2 Al gIliter
Results are: The CAl (mI/mm) were (1) CCH12, 34.8 4.2; (2) CCCup,
24.6 5.4; (3) OCCup, 50.5 2.3; (4) 0CH12, 126.2 12.4; (5) HFF,
164.3 15.3 [P < 0.001 between (1) and (3), (2) and (3), (3) and (4), (4)
and (5)1. In conclusion, (1) higher CAI was obtained by open circuit
hemodialysis and a high permeability membrane, or by hemoflltration.
(2) These data should be considered in the treatment of aluminum
intoxication in hemodialyzed patients.
Ab (mI/mm) =
